RYR2 and Alzheimer disease: This demonstrates that dantrolene treatment has the ability to both normalize RyR calcium signaling abnormalities and reduce pathogenic Aβ42 production providing evidence that targeting intracellular calcium channels may be a viable candidate for AD treatment.